PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum)

Starting soon · Not applicable · Has a placebo group

Conditions studied: Pancreatic Cancer, Pancreatic Diseases, Gastrointestinal Symptoms, Clostridium Butyricum Miyairi, Pancreatoduodenectomy, CBM588

In brief

This is a prospective, randomized, double-blind, single-center clinical trial designed to evaluate the effects of Clostridium butyricum CBM588 supplementation on postoperative diarrhea, gastrointestinal symptoms, and quality of life in patients undergoing pancreaticoduodenectomy for periampullary neoplasms. Oncological outcomes, including disease-free survival and overall survival, will be monitored as secondary endpoints during follow-up.

Key facts

Study ID

NCT07422103

Run by

Casa di Cura Dott. Pederzoli

People needed

158

Starts

2026-03-15

Expected to finish

2030-11-30

Last updated by the study team

2026-02-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Written informed consent
• Patients undergoing pancreaticoduodenectomy
• Candidates for upfront surgery without previous neoadjuvant chemotherapy or radiotherapy
• Patients with benign or malignant periampullary neoplasms

You may not qualify if…

• Age < 18 years
• Previous or current use of Clostridium butyricum CBM588
• Lactose intolerance
• Neoadjuvant chemotherapy or radiotherapy

Where it is running

• Ospedale Pederzoli — Peschiera del Garda, Verona, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.